Recently, the recognition that mediastinal radiation is associated with significant longterm toxicities has led to the development of novel approaches for PMBL that have shown excellent efficacy and challenge the need for routine mediastinal radiation.
INTRODUCTION
Primary mediastinal B-cell lymphoma (PMBL), originally described in the 1980's, accounts for up to 10% of diffuse large B-cell lymphomas (DLBCL). It is epidemiologically, clinically and biologically distinct from the other subtypes of DLBCL (germinal center B-cell like (GCB) and activated B-cell like (ABC)). Similar to nodular sclerosing Hodgkin lymphoma (NSHL) arising in the mediastinum, it is likely derived from a thymic B-cell and typically presents in adolescents and young adults with an anterior mediastinal mass, which may invade local structures. Studies of gene expression profiling demonstrate a significant overlap between PMBL and NSHL and interestingly, The optimal therapeutic approach to PMBL is controversial with a paucity of prospective studies. Though there are many retrospective studies, one of the challenges in interpreting them is that older studies likely included cases that would not meet the clinicopathologic definition of PMBL today. For the most part, it has been treated in the same way as the other subtypes of DLBCL with R-CHOP. However, the high efficacy of increased dose intensity regimens in this disease suggests that it requires a unique therapeutic approach. The major controversies in PMBL therapeutics are the need for consolidation radiation, the role of FDG-PET scanning and whether or not there are superior chemotherapy platforms to CHOP.
CLINICAL FEATURES
PMBL usually affects adolescents and young adults, with a female propensity, and typically presents in the third and fourth decades of life, which is much earlier than the other subtypes of DLBCL(1). Symptoms at diagnosis are typically caused by an anterior mediastinal mass and complications such as the superior vena cava (SVC) syndrome are common at presentation. PMBL tends to stay confined to the mediastinum and sometimes, may invade local structures such as the anterior chest wall and lungs.
Disseminated disease may occur at diagnosis when extranodal sites such as the kidney, liver and adrenal gland may be involved. Nodular sclerosing Hodgkin lymphomaarising in the mediastinum -shares many clinical characteristics with PMBL and also typically presents in young females. Recently, mediastinal grey zone lymphomas 
Pathology
PMBL is putatively derived from a medullary thymic B-cell. Morphologically, these are medium to large cells having round or lobulated nuclei and abundant cytoplasm.
In most cases, compartmentalizing sclerosis is observed and sometimes tumor cells can resemble Hodgkin/Reed Sternberg cells. The nodal architecture is typically diffuse with occasional cases showing focal nodularity and necrosis is sometimes seen(3). PMBL has a B-cell phenotype and expresses CD20 and pan B-cell markers such as CD79a, but tumor cells do not express surface immunoglobulin-therefore, monoclonality can not be established by kappa and lambda staining in contrast to most B-cell neoplasms (4, 5). Bcell transcription factors including PAX5, OCT2 and BOB1 are typically strongly expressed. CD30 is typically expressed but is dim in comparison to classical HL whereas CD15 is usually negative (3-5). The germinal center markers CD10, BCL6 and CD23 are expressed in most cases of PMBL, in keeping with its thymic B-cell origin(6, 7).
Distinguishing PMBL from nodular sclerosis Hodgkin lymphoma can sometimes be challenging for the pathologist -NSHL has a nodular pattern of growth and the presence of lacunar variants of HRS cells with a characteristic immunophenotype. In contrast to PMBL, cells are typically CD15 positive and strongly positive for CD30. The expression of B-cell markers like CD20, CD79a and PAX5 is often weak or negative (8, 9) .
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From history and physical examination, complete evaluation of hematological and biochemical parameters, computerized tomography of the chest, abdomen and pelvis and a bone marrow aspirate and biopsy should be performed. Though CNS involvement is very rare at initial diagnosis, the CSF should be checked by cytology and flow cytometry in the presence of clinical characteristics that are associated with a higher risk of CNS spread(22). It is common for pleural and pericardial effusions to occur at presentation so it may be useful to perform an echocardiogram. While the international prognostic index (IPI) is useful in DLBCL, its utility in PMBL specifically is limited by the young age distribution of the disease and its typical confinement to the mediastinum(23). Various studies have looked at the role of IPI but it is not clear that it is helpful in predicting outcome (24). Some retrospective studies have suggested that factors like LDH level, male sex, performance status and advanced stage disease may be useful predictors of survival but this is controversial and has not been validated in prospective studies (25, 26 ).
Primary Treatment and Outcome
As PMBL is relatively rare and only recently described, there is a paucity of prospective treatment data and a lack of randomized studies. Therefore controversies abound about what the optimal therapeutic approach should be and which regimen is best. The cure rate for progressive or recurrent disease following primary therapy is low so it is critical to optimize up-front outcomes. Most effective approaches to date have incorporated consolidation radiation -though high cure rates are achieved with combined modality therapy, it is increasingly apparent, especially from follow-up data on long-term (27, 28) . Though some studies suggest that lower doses of radiation and more focused treatment fields may reduce these complications, this has not been clearly demonstrated and some studies contest this(29).
It is therefore important in PMBL to develop platforms that obviate the need for routine radiation and thus eliminate these complications.
Radiation and Dose Intensity
Early studies in PMBL suggested that consolidation radiation was a critical component of curative therapy. One of these that led to this widely held acceptance was a study of MACOP-B (methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin) followed by mediastinal radiation therapy in 50 untreated PMBL patients(30). While 66% of patients were gallium scan positive (this study was done in the pre FDG-PET era) at the end of chemotherapy, only 19% were gallium positive after radiation and this supported a combined modality approach, which is taken by most today. Early (albeit retrospective) studies also suggested a benefit to increasing dose intensity, which has been shown to be important in Hodgkin lymphoma, a closely related disease clinically and biologically. One such study retrospectively compared MACOP-B and VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) to CHOP in 138 patients -those who received CHOP had a worse outcome, suggesting a role for dose-intensity(31). The largest study to look at the dose intensity question was conducted by the International Extranodal Lymphoma Study Group (IELSG) and evaluated 426 newly diagnosed PMBL patients who received
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From MACOP-B, VACOP-B, ProMACECytaBom or CHOP (26). Although response rates were similar among the groups, projected long-term PFS and OS survival rates were higher in patients who received third-generation regimens. Additional retrospective series from the British Columbia Cancer Agency and MSKCC groups also suggested that increased dose-intensity regimens might be superior to CHOP-like approaches in this disease (24, 25) . Nonetheless, prospective comparisons of increased dose-intensity versus CHOP-like regimens have not been done in PMBL -though the Southwest Oncology Group (SWOG) prospectively compared second and third generation regimens to CHOP in DLBCL, the outcome of PMBL was not assessed as it was not a recognized disease entity at this time(32).
The Role of Rituximab
While the addition of rituximab to CHOP chemotherapy in DLBCL has been shown to improve survival in several different studies, this has not been well studied or established in PMBL due to the rarity of the disease(33). A subgroup analysis of the prospective, randomized, phase III MabThera International Trial (MInT) evaluated the role of rituximab in combination with CHOP-like regimens in PMBL patients with an age adjusted IPI of ≤ 1 (34). The rituximab arm was clearly superior in terms of 3-year eventfree survival (78% versus 52% in the chemotherapy arm alone), but no statistically significant difference in OS was detected due to small numbers of patients. When the outcome of patients who received DA-EPOCH alone in the pre-rituximab era was compared to those who received DA-EPOCH-R, albeit a non-randomized comparison, there was a significantly better event-free and overall survival in the group who received In addition and importantly, the study was confined to patients with a low IPI score (≤1) who truly represent very favorable subset of patients without the presence of unfavorable characteristics at diagnosis. A recent retrospective analysis of R-CHOP (followed by mediastinal radiation in 77% of responders) in 58 PMBL patients that included all IPI groups showed a high rate of primary induction failures (21%) and an overall PFS of 68% at 5 years(37). Another retrospective analysis from the MSKCC group evaluated R-CHOP followed by ifosfamide, cyclophosphamide and etoposide (ICE) without radiation and reported a PFS of 78% at 3 years(38). A British Columbia study that looked at the outcome of PMBL in the rituximab era reported on a subset of patients in whom an FDG-PET guided RT approach (i.e. FDG-PET negative cases were not radiated) was used. 
Therapeutic Decision Making
In making decisions about the initial treatment of PMBL, one must consider the long-term complications of mediastinal radiation in this population who are predominantly young females(27). While R-CHOP followed by radiation has been effective in low-risk patients, it appears to be insufficient therapy for patients with highrisk disease and is associated with a high rate of primary refractory disease(44). Based on its promising efficacy in an NCI study, we recommend DA-EPOCH-R without radiation while confirmatory studies are in progress. Following this regimen without radiation, end of therapy FDG-PET has an excellent negative predictive value but low positive predictive value so end of therapy positive FDG-PETs need to be interpreted cautiously with regard to decisions about consolidation radiation. A prospective study of FDG-PET directed therapy by the IELSG is currently underway.
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Treatment of Mediastinal grey-zone lymphomas
These very rare tumors have histological and immunophenotypic features that are transitional between PMBL and nodular sclerosing Hodgkin lymphoma. Due to their rarity and recent identification, they have been poorly studied. In the past, these tumors were likely called "anaplastic large-cell lymphoma Hodgkin-like" and that entity was reported to have a poor prognosis with short median survivals(45). Their indeterminate pathobiology has led to uncertainty about what the optimal therapeutic strategy should be. One retrospective study reported that the 5-year event-free survival for this entity was worse than that for classical Hodgkin lymphoma (International Database on Hodgkin's Disease), suggesting adverse biology and a high rate of treatment resistance (45).
Recently, a prospective study looked at the clinical characteristics and outcome of MGZL following treatment with DA-EPOCH-R and reported a worse outcome compared to that of PMBL, despite a patient population with similar clinical characteristics (EFS and OS of 62% and 74% versus 93% and 97% for PMBL) (46, 47). Studies investigating the molecular characteristics and biological basis for this inferior outcome are ongoing.
Treatment of relapsed or refractory disease
In PMBL, relapses tend to occur relatively early following the completion of treatment and most are observed in the first year or 18 months after therapy. Relapsed disease may stay confined to the mediastinum or spread to extra-nodal sites such as the liver, kidneys or central nervous system. . Optimal therapy for relapsed disease has not been well defined and should be decided based on the pattern of relapse and prior treatments received. For relapses that are localized to the mediastinum, chemotherapy with radiation treatment (with or without autologous stem cell transplantation) may be a curative option, especially in patients who did not receive mediastinal radiation initially.
For non-localized relapses, salvage chemotherapy followed by high dose therapy may be considered(48). Allogeneic transplantation is another experimental option that can be considered. The outcome for patients with MGZL is inferior to that of PMBL and relapses should be approached similarly to PMBL.
Novel Agents
The antibody drug conjugate directed against CD30 -brentuximab vedotin -has shown activity in patients with relapsed Hodgkin lymphoma and is currently being studied in PMBL, where CD30 is variably expressed ( Controversies abound as to what the optimal regimen is for PMBL but evidence from several studies suggests a benefit to regimens with increased dose-intensity.
Recent data demonstrates that DA-EPOCH-R can obviate the need for routine mediastinal radiation. These results are now being validated in multicenter settings in distinct patient groups. Though FDG-PET is routinely used for end of treatment assessment in PMBL, it has a low positive predictive value that limits its usefulness in the assessment of residual masses. R e f e r e n c e s 
